Takeda Pharmaceutical Company Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TKPHF | MOREPENLAB.NS | INDSWFTLAB.BO | STAR.NS | 4547.T | 4534.T | |
|---|---|---|---|---|---|---|
| Market cap | 66.85B | 53.21B | 31.50B | 92.87B | 161.53B | 119.24B |
| P/E (TTM) | 298.9 | 28.3 | 37.0 | 15.1 | 14.4 | 13.1 |
| Forward P/E | 51.7 | — | — | 11.7 | 17.6 | 18.1 |
| Price/book | 1.4 | 3.9 | 2.1 | 2.7 | 0.7 | 0.9 |
| Dividend yield | 3.08% | 0.20% | — | 0.49% | 3.46% | 2.60% |
| 1-year change | +54.73% | +113.46% | +268.15% | +5.71% | −6.36% | +7.91% |
| Today | +2.30% | −4.17% | −4.09% | −0.65% | +3.06% | +3.66% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All TKPHF news ›Takeda Pharmaceutical's Earnings Growth Has Yet To Translate To Higher Cash Flow
Takeda Pharmaceutical is reiterated as a hold, with concerns about its ability to replace major drug revenues and current valuation. Read more on TAK stock here. - Takeda Pharmaceutical is reiterated as a Hold, with concerns about its…
Bernstein Keeps Their Hold Rating on Takeda Pharmaceutical Co (TKPHF)
In a report released on January 16, Miki Sogi from Bernstein maintained a Hold rating on Takeda Pharmaceutical Co, with a price target of Yen4,700.00. The company’s shares closed last Tuesday at Yen5,073.00. Sogi covers the Healthcare…
Takeda Pharmaceutical Raises Annual Guidance
Published on 10/29/2026 at 03:28 am EDT - Modified on 10/29/2026 at 03:29 am EDT Takeda Pharmaceutical raised its annual earnings forecasts, after swinging to a net profit in the second quarter. The Japanese drugmaker on Thursday reported…
Takeda Pharmaceutical (NYSE:TAK) Posts Earnings Results, Beats Expectations By $0.37 EPS
Posted by Danessa Lincoln on Oct 30th, 2026 Takeda Pharmaceutical (NYSE:TAK – Get Free Report) issued its quarterly earnings data on Thursday. The company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.14 by…
Takeda Pharmaceutical Eyes 2027 Japan Filing for Gastric Cancer Treatment
Takeda Pharmaceutical is targeting 2027 to file for regulatory approval in Japan for its experimental gastric cancer drug, arcotatug tavatecan, following positive results from a phase 3 clinical... Takeda Pharmaceutical Company Limited…
Takeda Pharmaceutical Company Limited 2026 Q2 - Results - Earnings Call Presentation
2026-10-30. The following slide deck was published by Takeda Pharmaceutical Company Limited in conjunction with their 2026 Q2 earnings call. The following slide deck was published by Takeda Pharmaceutical Company Limited in conjunction…
Takeda Pharmaceutical Non-GAAP EPS of ¥308.00, revenue of ¥2407B; upgrades FY 2026 outlook
Takeda Pharmaceutical reports 1H revenue up 8.4% year over year and non-GAAP EPS of ¥308. - Takeda Pharmaceutical press release (TAK): 1H Non-GAAP EPS of ¥308.00. - Adjusted Free Cash Flow was JPY 325.7 billion. - FY2026 full-year outlook…
Takeda Pharmaceutical (TAK) Expected to Announce Earnings on Thursday
Posted by Danessa Lincoln on Oct 27th, 2026 Check Out Our Latest Research Report on TAK Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain…
Takeda Pharmaceutical TAK Clears Its 52-Week High at $19.45
As seen on the 24/7 Wall St. homepage on October 15, 2026. Takeda Pharmaceutical touched $19.45, a fresh 52-week high that clears the September 17 peak by 2.1%. The ADR and the OTC line are both at the top of their range. Takeda…
Takeda Pharmaceutical Company Limited Presents Phase 2/3 IgGNITE Study Results Of Investigational Subcutaneous TAK-881 In Primary Immunodeficiency Disease At ESID 2026
Published on 10/14/2026 at 09:37 am EDT 11.9 g/L) were above accepted protective thresholds against infections. Delivering equivalent bodyweight-adjusted IG dosing in a concentrated 20% solution reduced total infusion volume by 50%. This…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com7
- seekingalpha.com4
- themarketsdaily.com3
- theglobeandmail.com2
- 247wallst.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 19 articles, not a forecast.